SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.1% – Should You Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was down 6.1% during trading on Thursday . The company traded as low as $8.41 and last traded at $8.4270. Approximately 3,462,138 shares traded hands during trading, a decline of 55% from the average daily volume of 7,707,157 shares. The stock had previously closed at $8.97.

Analyst Upgrades and Downgrades

A number of research analysts have commented on SLS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Tuesday, April 21st. Maxim Group increased their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and an average price target of $10.00.

SELLAS Life Sciences Group Trading Down 18.7%

The stock’s 50-day moving average price is $5.20 and its 200-day moving average price is $3.87. The company has a market capitalization of $1.36 billion, a P/E ratio of -31.39 and a beta of 2.24.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SLS. Axxcess Wealth Management LLC bought a new position in shares of SELLAS Life Sciences Group in the 3rd quarter worth about $26,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth about $26,000. BNP Paribas Financial Markets lifted its position in shares of SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock worth $32,000 after buying an additional 9,299 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth about $38,000. Finally, Beacon Pointe Advisors LLC bought a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth about $38,000. 17.38% of the stock is currently owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.